Claims for Patent: 8,883,832

Summary for Patent: 8,883,832

Title:	Compounds, compositions, and methods for preventing metastasis of cancer cells
Abstract:	Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.
Inventor(s):	Shalwitz; Robert (Bexley, OH), Peters; Kevin Gene (Cincinnati, OH)
Assignee:	Aerpio Therapeutics Inc. (Cincinnati, OH)
Application Number:	13/783,311
Patent Claims:	1. A method for treating a subject with cancer, comprising administering to the subject and effective amount of a compound having the formula: ##STR00221## wherein R is a substituted or unsubstituted thiazolyl unit having the formula: ##STR00222## R.sup.2, R.sup.3, and R.sup.4 are each independently: i) hydrogen; ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C.sub.2-C.sub.6 linear, branched, or cyclic alkenyl; iv) substituted or unsubstituted C.sub.2-C.sub.6 linear or branched alkynyl; v) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; vi) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl; vii) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic; or viii) R.sup.2 and R.sup.3 can be taken together to form a saturated or unsaturated ring having from 5 to 7 atoms; wherein from 1 to 3 atoms can optionally be heteroatoms chosen from oxygen, nitrogen, and sulfur; Z is a unit having the formula: -(L).sub.n-R.sup.1 R.sup.1 is chosen from: i) hydrogen; ii) hydroxyl; iii) amino; iv) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched or cyclic alkyl; v) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched or cyclic alkoxy; vi) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; vii) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic rings; or viii) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl rings; L is a linking unit having the formula: -[Q].sub.y[C(R.sup.5aR.sup.5b)].sub.x[Q.sup.1].sub.z[C(R.sup.6aR.sup.6b)- ].sub.w-- Q and Q.sup.1 are each independently: i) --C(O)--; ii) --NH--; iii) --C(O)NH--; iv) --NHC(O)--; v) --NHC(O)NH--; vi) --NHC(O)O--; vii) --C(O)O--; viii) --C(O)NHC(O)--; ix) --O--; x) --S--; xi) --SO.sub.2--; xii) --C(.dbd.NH)--; xiii) --C(.dbd.NH)NH--; xiv) --NHC(.dbd.NH)--; or xv) --NHC(.dbd.NH)NH--; R.sup.5a and R.sup.5b are each independently: i) hydrogen; ii) hydroxy; iii) halogen; iv) C.sub.1-C.sub.6 substituted or unsubstituted linear or branched alkyl; or v) a unit having the formula: --[C(R.sup.7aR.sup.7b)].sub.tR.sup.8 R.sup.7a and R.sup.7b are each independently: i) hydrogen; or ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; R.sup.8 is: i) hydrogen; ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl; iii) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; iv) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl; or v) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic; R.sup.6a and R.sup.6b are each independently: i) hydrogen; or ii) C.sub.1-C.sub.4 linear or branched alkyl; the index n is 0 or 1; the indices t, w and x are each independently from 0 to 4; the indices y and z are each independently 0 or 1; or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1, further comprising administering one or more chemotherapeutic agents. 3. The method according to claim 2, wherein the chemotherapeutic agent is chosen from vincristine, vinblastine, vindesine, vinorelbine-5'-noranhydroblastine, irinotecan, topotecan, cisplatin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, belustine, chlomaphazin, dacarbazine, cytosine arabinoside, fluorouracil, methotrexate, mercaptopurine, azathioprime, procarbazine, doxorubicin, bleomycin, dactinomycin, daunorubicin, mithramycin, mitomycin, mytomycin C, daunomycin, azacytidine, amsacrine, melphalan, ifosfamide, mitoxantrone, cis-platin, etoposide, taxol, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; anastrozole; anthramycin; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; brequinar sodium; bropirimine; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carubicin hydrochloride; carzelesin; cedefingol; cirolemycin; cladribine; crisnatol mesylate; cytarabine; decitabine; dexormaplatin; dezaguanine; diaziquone; docetaxel; droloxifene; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; etanidazole; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; hydroxyurea; idarubicin hydrochloride; ilmofosine; interleukin II interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; menogaril; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitosper; mitotane; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; puromycin; pyrazofurin; riboprine; rogletimide; safingol; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; triptorelin; tubulozole hydrochloride; uredepa; vapreotide; verteporfin; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; and zorubicin hydrochloride. 4. The method according to claim 2, wherein the chemotherapeutic agent is chosen from taxol, IL-2, gemcitabine, erlotinib, doxil, irinortecan, and bevacizumab. 5. The method according to claim 2 wherein the compound is administered prior to administration of the chemotherapeutic agent. 6. The method according to claim 2 wherein the compound is administered together with each administration of the chemotherapeutic agent. 7. The method according to claim 2, wherein the compound is administered each time the chemotherapeutic agent is administered and between administrations of the chemotherapeutic agent. 8. The method according to claim 1, wherein the method further comprises radiation therapy. 9. The method according to claim 8, wherein the compound is administered at the time of radiation therapy. 10. The method according to claim 8, wherein the compound is administered prior to the onset of radiation therapy. 11. The method according to claim 8, wherein the compound is administered after radiation therapy. 12. The method according to claim 8, wherein the compound is administered at the time of each radiation therapy and between each subsequent administration of radiation therapy. 13. The method according to claim 1, wherein R has the formula: ##STR00223## 14. The method according to claim 1, wherein R.sup.2 is chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl; and R.sup.3 is hydrogen. 15. A method according to claim 1, wherein R.sup.2 is an alkyl unit wherein one or more hydrogen atoms are substituted with one or more substitutions chosen from: i) halogen; ii) --N(R.sup.11).sub.2; and iii) --OR.sup.11; wherein each R.sup.11 is independently hydrogen or C.sub.1-C.sub.4 linear or branched alkyl. 16. The method according to claim 1, wherein R.sup.2 is substituted or unsubstituted phenyl and R.sup.3 is hydrogen. 17. The method according to claim 1, wherein R.sup.2 is substituted or unsubstituted heteroaryl and R.sup.3 is hydrogen. 18. The method according to claim 1, wherein R.sup.2 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, or [1,3,4]thiadiazol-2-yl. 19. The method according to claim 1, wherein R.sup.2 is thiophen-2-yl or thiophen-3-yl. 20. The method according to claim 1, wherein R has the formula: ##STR00224## 21. The method according to claim 1, wherein R.sup.4 is hydrogen or substituted or unsubstituted C.sub.1-C.sub.6 linear, branched, or cyclic alkyl. 22. The method according to claim 1, wherein R.sup.4 is chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and tert-butyl; and R.sup.3 is hydrogen. 23. The method according to claim 1, wherein R.sup.4 is substituted or unsubstituted phenyl and R.sup.3 is hydrogen. 24. The method according to claim 1, wherein R.sup.4 is an alkyl unit wherein one or more hydrogen atoms are substituted with one or more substitutions chosen from: i) halogen; ii) --N(R.sup.11).sub.2; and iii) --OR.sup.1; wherein each R.sup.11 is independently hydrogen or C.sub.1-C.sub.4 linear or C.sub.3-C.sub.4 branched alkyl. 25. The method according to claim 1, wherein R.sup.4 is substituted or unsubstituted heteroaryl. 26. The method according to claim 1, wherein R.sup.4 is a heteroaryl unit chosen from 1,2,3,4-tetrazol-1-yl, 1,2,3,4-tetrazol-5-yl, [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, [1,2,4]triazol-5-yl, imidazol-2-yl, imidazol-4-yl, pyrrol-2-yl, pyrrol-3-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]oxadiazol-5-yl, [1,3,4]oxadiazol-2-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, [1,2,4]thiadiazol-3-yl, [1,2,4]thiadiazol-5-yl, and [1,3,4]thiadiazol-2-yl. 27. The method according to claim 1, wherein R.sup.4 is thiophen-2-yl or thiophen-3-yl. 28. The method according to claim 1, wherein R.sup.1 is hydrogen, methyl, ethyl, tert-butyl, or methyl substituted with phenyl. 29. The method according to claim 1, wherein L has the formula: --C(O)[C(R.sup.5aR.sup.5b)].sub.xNHC(O)-- R.sup.5a is hydrogen, substituted or unsubstituted phenyl, and substituted or unsubstituted heteroaryl; the index x is 1 or 2. 30. The method according to claim 1, wherein L has the formula chosen from: i) --C(O)[C(R.sup.5aH)]NHC(O)O--; ii) --C(O)[C(R.sup.5aH)][CH.sub.2]NHC(O)O--; ii) --C(O)[CH.sub.2][C(R.sup.5aH)]NHC(O)O--; iv) --C(O)[C(R.sup.5aH)]NHC(O)--; v) --C(O)[C(R.sup.5aH)][CH.sub.2]NHC(O)--; or vi) --C(O)[CH.sub.2][C(R.sup.5aH)]NHC(O)--; wherein R.sup.5a is: i) hydrogen; ii) methyl; iii) ethyl; iv) isopropyl; v) phenyl; vi) benzyl; vii) 4-hydroxybenzyl; viii) hydroxymethyl; or ix) 1-hydroxyethyl. 31. The method according to claim 1, wherein R.sup.1 is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, and 3,5-dimethoxyphenyl. 32. The method according to claim 1, wherein R.sup.2 is methyl or ethyl, R.sup.3 is hydrogen, and L has the formula --C(O)CH.sub.2--. 33. The method according to claim 1, wherein R.sup.2 is methyl or ethyl, R.sup.3 is hydrogen, and L has the formula --C(O)CH.sub.2CH.sub.2--. 34. The method according to claim 3, wherein R.sup.1 is a substituted or unsubstituted heteroaryl unit, said substitutions chosen from: i) C.sub.1-C.sub.6 linear, C.sub.3-C.sub.6 branched, and C.sub.3-C.sub.6 cyclic alkyl; ii) substituted or unsubstituted phenyl and benzyl; iii) substituted of unsubstituted heteroaryl; iv) --C(O)R.sup.9; or v) --NHC(O)R.sup.9; R.sup.9 is C.sub.1-C.sub.6 linear or C.sub.3-C.sub.6 branched alkyl; C.sub.1-C.sub.6 linear or C.sub.3-C.sub.6 branched alkoxy; or --NHCH.sub.2C(O)R.sup.10; R.sup.10 is chosen from hydrogen, methyl, ethyl, or tert-butyl. 35. The method according to claim 1, wherein R.sup.1 is a heteroaryl unit substituted by an alkyl unit chosen from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, or tert-butyl. 36. The method according to claim 1, wherein R.sup.1 is a heteroaryl unit substituted by a carboxy unit having the formula --NHC(O)R.sup.9; R.sup.9 is chosen from methyl, methoxy, ethyl, ethoxy, tert-butyl, and tert-butoxy. 37. The method according to claim 1, wherein the compound has the formula: ##STR00225## wherein R.sup.2 is methyl or ethyl, R.sup.3 is hydrogen, R.sup.6a is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3-methyl-1,2,4-oxadiazol-5-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, or isoxazol-3-yl. 38. The method according to claim 1, wherein the compound has the formula: ##STR00226## wherein R.sup.4 is methyl, ethyl, phenyl, or thiophen-2-yl, R.sup.6a is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 3-methyl-1,2,4-oxadiazol-5-yl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, or isoxazol-3-yl. 39. The method according to claim 1, wherein the compound has the formula: ##STR00227## wherein R.sup.2 is chosen from methyl, ethyl, phenyl, and thiophen-2-yl, R.sup.3 is hydrogen or methyl; R.sup.1 is chosen from phenyl, thiophen-2-yl, thiophen-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, and isoxazol-3-yl. 40. The method according to claim 1, wherein the compound has the formula: ##STR00228## wherein R.sup.2 and R.sup.3 are each independently hydrogen, methyl or ethyl; R.sup.1 is chosen from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, and 3,5-dimethoxyphenyl. 41. The method according to claim 1, wherein R.sup.1 is a substituted or unsubstituted heteroaryl unit chosen from: i) 1,2,3,4-tetrazol-1-yl and 1,2,3,4-tetrazol-5-yl having the respective formulae: ##STR00229## ii) [1,2,3]triazol-4-yl, [1,2,3]triazol-5-yl, [1,2,4]triazol-4-yl, and [1,2,4]triazol-5-yl having the respective formulae: ##STR00230## iii) imidazol-2-yl and imidazol-4-yl having the respective formulae: ##STR00231## iv) pyrrol-2-yl and pyrrol-3-yl having the respective formulae: ##STR00232## v) oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl having the respective formulae: ##STR00233## vi) isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl having the respective formulae: ##STR00234## vii) [1,2,4]oxadiazol-3-yl and [1,2,4]oxadiazol-5-yl having the respective formulae: ##STR00235## viii) [1,3,4]oxadiazol-2-yl having the formula: ##STR00236## ix) furan-2-yl and furan-3-yl having the respective formulae: ##STR00237## x) thiophen-2-yl and thiophen-3-yl having the respective formulae: ##STR00238## xi) isothiazol-3-yl, isothiazol-4-yl and isothiazol-5-yl having the respective formulae: ##STR00239## xii) thiazol-2-yl, thiazol-4-yl and thiazol-5-yl having the respective formulae: ##STR00240## and xiii) [1,2,4]thiadiazol-3-yl and [1,2,4]thiadiazol-5-yl having the respective formulae: ##STR00241## said heteroaryl unit substitutions chosen from: i) C.sub.1-C.sub.6 linear, C.sub.3-C.sub.6 branched, C.sub.3-C.sub.6 and cyclic alkyl; ii) substituted or unsubstituted phenyl and benzyl; iii) substituted of unsubstituted heteroaryl; iv) --C(O)R.sup.9; and v) --NHC(O)R.sup.9; R.sup.9 is C.sub.1-C.sub.6 linear and branched alkyl; C.sub.1-C.sub.6 linear and C.sub.3-C.sub.6 branched alkoxy; or --NHCH.sub.2C(O)R.sup.10; R.sup.10 is chosen from hydrogen, methyl, ethyl, and tert-butyl; R.sup.4 is a unit chosen from: i) hydrogen; ii) substituted or unsubstituted C.sub.1-C.sub.6 linear, C.sub.3-C.sub.6 branched, or C.sub.3-C.sub.6 cyclic alkyl; iii) substituted or unsubstituted C.sub.2-C.sub.6 linear, C.sub.3-C.sub.6 branched, or C.sub.3-C.sub.6 cyclic alkenyl; iv) substituted or unsubstituted C.sub.2-C.sub.6 linear or C.sub.3-C.sub.6 branched alkynyl; v) substituted or unsubstituted C.sub.6 or C.sub.10 aryl; vi) substituted or unsubstituted C.sub.1-C.sub.9 heteroaryl; vii) substituted or unsubstituted C.sub.1-C.sub.9 heterocyclic. 42. The method according to claim 1, wherein the compound is chosen from: (S)-4-[2-Benzamido-2-(4-ethylthiazol-2-yl)ethyl]phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(2-fluorophenyl)acetamido]ethyl}pheny- l-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(3-fluorophenyl)acetamido)ethyl)pheny- lsulfamic acid; (S)-4-(2-(2-(2,3-Difluorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)p- henyl-sulfamic acid; (S)-4-(2-(2-(3,4-Difluorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)p- henyl-sulfamic acid; (S)-4-(2-(2-(2-Chlorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)pheny- lsulfamic acid; (S)-4-(2-(2-(3-Chlorophenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)pheny- l-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(3-hydroxyphenyl)acetamido)ethyl)phen- yl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(2-methoxyphenyl)acetamido)ethyl)phen- yl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(2-(3-methoxyphenyl)acetamido)ethyl)phen- yl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-phenylpropanamido)ethyl)phenylsulfami- c acid; (S)-4-(2-(2-(3,4-Dimethoxyphenyl)acetamido)-2-(4-ethylthiazol-2-yl- )ethyl)-phenylsulfamic acid; (S)-4-(2-(2-(2,3-Dimethoxyphenyl)acetamido)-2-(4-ethylthiazol-2-yl)ethyl)- -phenylsulfamic acid; (S)-4-(2-(3-(3-Chlorophenyl)propanamido)-2-(4-ethylthiazol-2-yl)ethyl)phe- nyl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(2-methoxyphenyl)propanamido)ethyl)ph- enyl-sulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(3-methoxyphenyl)propanamido)ethyl)ph- eny-lsulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(3-(4-methoxyphenyl)propanamido)ethyl)ph- enyl-sulfamic acid; (S)-4-{2-[2-(4-Ethyl-2,3-dioxopiperazin-1-yl)acetamido]-2-(4-ethylthiazol- -2-yl)ethyl}phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(5-methyl-2,4-dioxo-3,4-dihydropyrimi- din-1(2H)-yl)acetamide]ethyl}phenylsulfamic acid; (S)-4-[2-(Benzo[d][1,3]dioxole-5-carboxamido)-2-(4-ethylthiazol-2-yl)ethy- l]-phenylsulfamic acid; 4-((S)-2-(2-(2-Chlorophenyl)acetamido)-2-(2-(thiophene2-yl)thiazol-4-yl)e- thyl)-phenylsulfamic acid; 4-((S)-2-(2-(3-Methoxyphenyl)acetamido)-2-(2-(thiophene2-yl)thiazol-4-yl)- ethyl)-phenylsulfamic acid; 4-{(S)-2-(3-Phenylpropanamido)-2-[2-(thiophene2-yl)thiazol-4-yl]ethyl}phe- nyl-sulfamic acid; 4-{(S)-2-(3-(3-Chlorophenyl)propanamido)-2-[2-(thiophene2-yl)thiazol-4-yl- ]ethyl}-phenylsulfamic acid; 4-{(S)-2-[2-(3-Fluorophenyl)acetamide]-2-[2-(thiophene2-yl)thiazol-4-yl]e- thyl}-phenylsulfamic acid; (S)-4-{2-[2-(2,5-Dimethylthiazol-4-yl)acetamide]-2-(4-ethylthiazol-2-yl]e- thyl}-phenylsulfamic acid; (S)-4-{2-[2-(2,4-Dimethylthiazol-5-yl)acetamide]-2-(4-methylthiazol-2-yle- thyl}-phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[3-(thiazol-2-yl)propanamido]ethyl}pheny- lsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(4-ethylthiazol-2-yl)acetamide]ethyl}- phenyl-sulfamic acid; (S)-4-{2-[2-(3-Methyl-1,2,4-oxadiazol-5-yl)acetamide]-2-(2-phenylthiazol-- 4-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[2-(4-Ethyl-2,3-dioxopiperazin-1-yl)acetamide]-2-[2-(thiophen-2-- yl)thiazol-4-yl]ethyl}phenylsulfamic acid; (S)-4-(2-(2,3-Diphenylpropanamido)-2-(4-ethylthiazol-2-yl)ethyl)phenylsul- famic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(2-methoxyphenyl)-3-phenylpropanamido- ]-ethyl)phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(3-fluorophenyl)-3-phenylpropanamido]- -ethyl}phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(3-methoxyphenyl)-3-phenylpropanamido- ]-ethyl}phenylsulfamic acid; 4-{(S)-2-(4-Ethylthiazol-2-yl)-2-[2-(3-methyl-1,2,4-oxadiazol-5-yl)-3-phe- nylpropanamido]ethyl}phenylsulfamic acid; (S)-4-[2-(4-Ethylthiazol-2-yl)-2-(4-oxo-4-phenylbutanamido)-ethyl]phenyls- ulfamic acid; (S)-4-(2-(4-Ethylthiazol-2-yl)-2-(5-methyl-4-oxohexanamido)ethyl)phenylsu- lfamic acid; (S)-4-{2-[4-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-4-oxobutanamido]-- 2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; (S)-4-{2-[4-(2,3-Dimethoxyphenyl)-4-oxobutanamido]-2-(4-ethylthiazol-2-yl- )ethyl}phenylsulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[4-oxo-4-(pyridin-2-yl)butanamido]ethyl}- phenyl-sulfamic acid; (S)-4-{2-[4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-4-oxobutanamido]-2-(4-e- thylthiazol-2-yl)ethyl}phenylsulfamic acid; (S)-4-[2-(4-tert-Butoxy-4-oxobutanamido)-2-(4-ethylthiazol-2-yl)ethyl]phe- nyl-sulfamic acid; (S)-4-[2-(4-Ethoxy-4-oxobutanamido)-2-(4-ethylthiazol-2-yl)ethyl]phenylsu- lfamic acid; (S)-4-(2-(3-Benzylureido)-2-(4-ethylthiazol-2-yl)ethyl)phenylsulfamic acid; 4-{[(S)-2-(2-Ethylthiazol-4-yl)-2-(3-(R)-1 methoxy-1-oxo-3-phenylpropan-2-yl)ureido]ethyl}phenylsulfamic acid; 4-{(S)-2-(3-Benzylureido)-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl}phenylsu- lfamic acid; {4-(S)-[2-Phenylmethanesulfonylamino-2-(2-thiophen-2-ylthiazol-4-yl)ethyl- ]-phenylsulfamic acid; 4-{(S)-2-[(2-Methylthiazol-4-yl)methylsulfonamido]-2-[2-(thiophen-2-yl)th- iazol-4-yl]ethyl}phenylsulfamic acid; {4-(S)-[2-Phenylmethanesulfonylamino-2-(2-ethylthiazol-4-yl)ethyl]phenyl}- -sulfamic acid; {4-(S)-[2-(3-Methoxyphenyl)methanesulfonylamino-2-(2-ethylthiazol-4-yl)et- hyl]phenyl}sulfamic acid; (S)-4-{[1-(2-Ethylthiazol-4-yl)-2-(4-sulfoaminophenyl)ethylsulfamoyl]meth- yl}-benzoic acid methyl ester; (S)-4-[2-(2-Ethylthiazol-4-yl)-2-(1-methyl-1H-imidazol-4-sulfonamido)ethy- l]-phenylsulfamic acid; 4-{(S)-2-[2-(Thiophen-2-yl)thiazol-4-yl]-2-(2,2,2-trifluoroethylsulfonami- do)-ethyl}phenylsulfamic acid; {4-(S)-[2-(Phenylethanesulfonylamino)-2-(2thiophen-2-ylthiazol-4-yl)ethyl- ]-phenyl}sulfamic acid; {4-(S)-[3-(Phenylpropanesulfonylamino)-2-(2thiophen-2-ylthiazol-4-yl)ethy- l]-phenyl}sulfamic acid; (S)-{4-[2-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazine-7-sulfonylamino)-2-(- 2-thiophen-2-ylthiazol-4-yl)ethyl]phenyl}sulfamic acid; 4-{(S)-2-(4-Acetamidophenylsulfonamido)-2-[2-(thiophen-2-yl)thiazol-4-yl]- ethyl}phenylsulfamic acid; 4-{(S)-2-(2-cyclopropylthiazol-4-yl)-2-[4-(3-methoxyphenyl)-thiazol-2-yla- mino]ethyl}phenylsulfamic acid; (S)-4-(2-(4-((2-Methoxy-2-oxoethyl)carbamoyl)thiazole-5-ylamino)-2-(2-eth- ylthiazole-4-yl)ethyl)phenylsulfamic acid; 4-((S)-2-(5-(1-N-(2-Methoxy-2-oxoethyl)-1-H-indol-3-yl)oxazole-2-ylamino)- -2-(2-methylthiazol-4-yl)ethyl))phenylsulfamic acid; 4-((S)-2-(5-(2-Methoxyphenyl)oxazol-2-ylamino)-2-(2-methylthiazol-4-yl)et- hyl)-phenylsulfamic acid; 4-((S)-2-(5-((S)-1-(tert-Butoxycarbonyl)-2-phenylethyl)oxazole-2-ylamino)- -2-(2-methylthiazole-4-yl)ethyl)phenylsulfamic acid; (S)-4-(2-(5-(4-Methoxycarbonyl)phenyl)oxazole-2-ylamino)-2-(2-methylthiaz- ole-4-yl)ethyl)phenylsulfamic acid; (S)-4-(2-(5-(3-Methoxybenzyl)oxazole-2-ylamino)-2-(2-methylthiazole-4-yl)- ethyl)-phenylsulfamic acid; (S)-4-(2-(2-Methylthiazole-4-yl)-2-(5-phenyloxazole-2-ylamino)ethyl)pheny- l-sulfamic acid; 4-((S)-2-(2-Cyclopropylthiazol-4-yl)-2-(4-(3-methoxyphenyl)thiazol-2-ylam- ino)-ethyl)phenylsulfamic acid; (S)-4-(2-(2-cyclopropylthiazol-4-yl)-2-(4-(4-fluorophenyl)thiazol-2-ylami- no)ethyl)-phenylsulfamic acid; 4-((S)-2-(2-cyclopropylthiazol-4-yl)-2-(4-(2-methoxyphenyl)thiazol-2-ylam- ino)-ethyl)phenylsulfamic acid; 4-((S)-2-(2-cyclopropylthiazol-4-yl)-2-(4-(2,4-difluorophenyl)thiazol-2-y- lamino)-ethyl)phenylsulfamic acid; (S)-4-(2-(4-(3-methoxybenzyl)thiazol-2-ylamino)-2-(2-cyclopropylthiazol-4- -yl)ethyl)phenylsulfamic acid; (S)-{5-[1-(2-Ethylthiazol-4-yl)-2-(4-sulfoaminophenyl)ethylamino]-2-methy- l-2H-[1,2,4]triazole-3-yl}carbamic acid methyl ester; 4-{(S)-2-[4-(2-Methoxyphenyl)thiazol-2-ylamino)-2-[2-(thiophen-2-yl)thiaz- ol-4-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[5-(3-Methoxyphenyl)oxazole-2-ylamino]-2-(2-phenylthiazole-4-yl)- ethyl}phenylsulfamic acid; 4-{(S)-2-[4-(2,4-Difluorophenyl)thiazol-2-ylamino]-2-[2-(thiophen-2-yl)th- iazol-4-yl]ethyl}phenylsulfamic acid; (S)-4-{2-[4-(Ethoxycarbonyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-yl)et- hyl}-phenylsulfamic acid; (S)-4-{2-[4-(2-Ethoxy-2-oxoethyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-- yl)ethyl}phenylsulfamic acid; (S)-4-{2-[4-(4-Acetamidophenyl)thiazol-2-ylamino]-2-(2-phenylthiazol-4-yl- )ethyl}phenylsulfamic acid; (S)-4-[2-(4-Phenylthiazol-2-ylamino)-2-(2-phenylthiazol-4-yl)ethyl]phenyl- sulfamic acid; (S)-4-{2-[4-(4-(Methoxycarbonyl)phenyl)thiazol-2-ylamino]-2-(2-phenylthia- zol-4-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[4-(Ethoxycarbonyl)thiazol-2-ylamino]-2-[2-(thiophen-2-yl)thiazo- l-4-yl]ethyl}phenylsulfamic acid; (S)-4-[2-(4-(Methoxycarbonyl)thiazol-5-ylamino)-2-(2-phenylthiazole-4-yl)- ethyl]-phenylsulfamic acid; (S)-4-[2-(5-Phenyloxazole-2-ylamino)]-2-(2-phenylthiazole-4-yl)phenylsulf- amic acid; (S)-4-{2-[5-(4-Acetamidophenyl)oxazole-2-ylamino]-2-(2-phenylth- iazole-4-yl)ethyl}phenylsufamic acid; 4-((S)-2-(5-(2,4-Difluorophenyl)oxazole-2-ylamino)-2-(2-phenylthiazole-4-- yl)ethyl)phenylsulfamic acid; 4-{(S)-2-[5-(3-Methoxyphenyl)oxazol-2-ylamino]-2-[(2-thiophen-2-yl)thiazo- le-4-yl]ethyl}phenylsulfamic acid; (S)-4-[2-(4,6-Dimethylpyrimidene-2-ylamino)-2-(2-methylthiazole-4-yl)ethy- l]-phenylsulfamic acid; (S)-4-[2-(4-Hydroxy-6-methylpyrimidine-2-ylamino)-2-(2-methylthiazole-4-y- l)ethyl]phenylsulfamic acid; 4-{(S)-2-[(S)-2-(tert-Butoxycarbonylamino)-3-phenylpropanamido]-2-(4-ethy- lthiazol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(R)-2-(tert-Butoxycarbonylamino)-3-phenylpropanamido]-2-(4-ethy- lthiazol-2-yl)ethyl}phenylsulfamic acid; {1-[1-(5-Ethylthiazol-2-yl)-(S)-2-(4-sulfoaminophenyl)ethylcarbamoyl]-(S)- -2-phenylethyl}methyl carbamic acid tert-butyl ester; {(S)-2-Phenyl-1-[1-(4-phenylthiazol-2-yl)-(S)-2-(4-sulfoaminophenyl)ethyl- -carbamoyl]ethyl}carbamic acid tert-butyl ester; 4-{(S)-2-(S)-2-(tert-Butoxycarbonylamino)-3-phenylpropaneamido-2-(2-pheny- lthiazole-4-yl)}phenylsulfamic acid; 4-{(S)-2-(4-Ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phenyl-p- ropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(thiazol-2-- yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(4-methylth- iazol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(4-propylth- iazol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-(4-tert-Butylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phe- nylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-(4-Cyclopropylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-ph- enylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-(4-Cyclohexylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phe- nyl-propanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-(4,5-Dimethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phe- nyl-propanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-Phenyl-1-[1-(2-phenylthiazol-4-yl)-(S)-2-(4-sulfoaminophenyl)eth- yl-carbamoyl]ethyl}carbamic acid tert-butyl ester; 4-{(S)-2-(4-Ethyl-5-methylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3- -phenyl-propanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[4-(2,2,2-t- rifluoroethyl)thiazol-2-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido)-2-[4-(3,3,3-t- rifluoropropyl)thiazol-2-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[4-(2,2-Difluorocyclopropyl)thiazol-2-yl]-2-[(S)-2-(methoxycarbo- nylamino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[4-(methoxy- -methyl)thiazol-2-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-(4-(Ethoxycarbonylamino)thiazol-2-yl)-2-[(S)-2-(methoxycarbonyla- mino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(5-phenylth- iazol-2-yl))ethyl}phenylsulfamic acid; 4-{(S)-2-(4-tert-Butylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phe- nyl-propanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-(4-Ethyl-5-phenylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3- -phenyl-propanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[4-(3,4-Dimethylphenyl)thiazol-2-yl]-2-[(S)-2-(methoxycarbonylam- ino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[4-(4-Chlorophenyl)thiazol-2-yl]-2-[(S)-2-(methoxycarbonylamino)- -3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(4-phenylth- iazol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[4-(thiophe- n-2-yl)thiazol-2-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[4-(thiophe- n-3-yl)thiazol-2-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-(4-Ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbinyl)-3-phenylpropion- -amido]ethyl}phenylsulfamic acid; 4-{(S)-2-(5,6-Dihydro-4H-cyclopenta[d]thiazol-2-yl)-2-[(S)-2-(methoxy-car- bonyl)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(4,5,6,7-te- trahydrobenzo[d]thiazol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[4-(5-Chlorothiophen-2-yl)thiazol-2-yl]-2-[(S)-2-(methoxycarbony- lamino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Ethoxycarbonylamino)-3-phenylpropanamido]-2-(4-ethylthia- zol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(2-ethylthi- azol-4-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(2-methyl-t- hiazol-4-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-(2-Ethylthiazole-4-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phenylp- ropan-amido]ethyl}phenylsulfamic acid; 4-{(S)-2-(2-Isopropylthiazol-4-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phen- yl-propan-amido]ethyl}phenylsulfamic acid; 4-{(S)-2-(2-Cyclopropylthiazol-4-yl)-2-[(S)-2-(methoxycarbonylamino)-3-ph- enylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-{2-[(4-Chlorophenylsulfonyl)methyl]thiazol-4-yl}-2-[(S)-2-(metho- xy-carbonyl)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[2-(tert-Butylsulfonylmethyl)thiazol-4-yl]-2-[(S)-2-(methoxycarb- onylamino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropionamido]-2-(2-phenyl-- thiazole-4-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(thiophe- n-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[2-(3-Chlorothiophen-2-yl)thiazol-4-yl]-2-[(S)-2-(methoxycarbony- lamino)-3-phenylpropanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(3-methy- lthiophen-2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-{[(S)-2-(2-(Furan-2-yl)thiazol-4-yl]-2-[(S)-2-(methoxycarbonylamino)-3-- phenyl-propanamido]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(2-methy- lthiazole-4-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(2-pyrazine- -2-yl)thiazole-4-yl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(6-methy- lpyridin-3-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-[(S)-2-((S)-2-Acetamido-3-phenylpropanamido)-2-(4-ethylthiazol-2-yl)eth- yl]-phenylsulfamic acid; 4-[(S)-2-((S)-2-Acetamido-3-phenylpropanamido)-2-(4-tert-butylthiazol-2-y- l)ethyl]-phenylsulfamic acid; 4-{(S)-2-((S)-2-Acetamido-3-phenylpropanamido)-2-[4-(thiophen-3-yl)thiazo- l-2-yl]ethyl)phenylsulfamic acid; 4-{(S)-2-[(S)-2-(tert-Butoxycarbonyl)-3-methylbutanamido]-2-(4-ethylthiaz- ol-2-yl)ethyl}phenylsulfamic acid; (S)-4-{2-[2-(tert-Butoxycarbonyl)acetamide]-2-(4-ethylthiazol-2-yl)ethyl}- phenyl-sulfamic acid; (S)-4-{2-(4-Ethylthiazol-2-yl)-2-[2-(methoxycarbonyl)acetamido]ethyl}phen- yl-sulfamic acid; 4-{(S)-2-(4-Ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonyl)-3-methylbutanam- ido]-ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(tert-Butoxycarbonyl)-4-methylpentanamido]-2-(4-ethylthia- zol-2-yl)ethyl}phenylsulfamic acid; 4-{(S)-2-(4-Ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonyl)-4-methylpentan-- amido]ethyl}phenylsulfamic acid; 4-((S)-2-(4-Ethylthiazol-2-yl)-2-{(S)-2-[2-(methoxycarbonyl)acetamide]-3-- phenylpropanamido}ethyl)phenylsulfamic acid; 4-{(S)-2-[(S)-2-(tert-Butoxycarbonyl)-4-methylpentanamido]-2-[2-(thiophen- -2-yl)thiazol-4-yl]ethyl}phenylsulfamic acid; 4-{(S)-2-[(S)-2-(Methoxycarbonyl)-4-methylpentanamido]-2-[2-(thiophen-2-y- l)thiazol-4-yl]ethyl}phenylsulfamic acid; and (S)-4-{2-[2-(tert-Butoxycarbonyl)acetamide]-2-(4-ethylthiazol-2-yl)ethyl}- -phenylsulfamic acid. 43. The method according to claim 1, wherein the compound has the formula: ##STR00242## and pharmaceutically acceptable salts thereof. 44. The method according to claim 43, wherein the method further comprises radiation therapy. 45. The method according to claim 1, wherein the compound has the formula: ##STR00243## and pharmaceutically acceptable salts thereof. 46. The method according to claim 45, wherein the method further comprises radiation therapy. 47. The method according to claim 1, wherein the compound has the formula: ##STR00244## and pharmaceutically acceptable salts thereof. 48. The method according to claim 1, wherein the method further comprises radiation therapy. 49. The method according to claim 1, wherein the compound has the formula: ##STR00245## and pharmaceutically acceptable salts thereof. 50. The method according to claim 49, wherein the method further comprises radiation therapy. 51. The method according to claim 1, wherein the cancer is chosen from Acute Lymphoblastic; Acute Myeloid Leukemia; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; Appendix Cancer; Basal Cell Carcinoma; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bone Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Childhood; Central Nervous System Embryonal Tumors; Cerebellar Astrocytoma; Cerebral Astrocytoma/Malignant Glioma; Craniopharyngioma; Ependymoblastoma; Ependymoma; Medulloblastoma; Medulloepithelioma; Pineal Parenchymal Tumors of Intermediate Differentiation; Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma; Visual Pathway and Hypothalamic Glioma; Brain and Spinal Cord Tumors; Breast Cancer; Bronchial Tumors; Burkitt Lymphoma; Carcinoid Tumor; Carcinoid Tumor, Gastrointestinal; Central Nervous System Atypical Teratoid/Rhabdoid Tumor; Central Nervous System Embryonal Tumors; Central Nervous System Lymphoma; Cerebellar Astrocytoma; Cerebral Astrocytoma/Malignant Glioma, Childhood; Cervical Cancer; Chordoma, Childhood; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Colon Cancer; Colorectal Cancer; Craniopharyngioma; Cutaneous T-Cell Lymphoma; Esophageal Cancer; Ewing Family of Tumors; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastrointestinal Carcinoid Tumor; Gastrointestinal Stromal Tumor (GIST); Germ Cell Tumor, Extracranial; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma; Glioma, Childhood Brain Stem; Glioma, Childhood Cerebral Astrocytoma; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer; Histiocytosis, Langerhans Cell; Hodgkin Lymphoma; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma; Intraocular Melanoma; Islet Cell Tumors; Kidney (Renal Cell) Cancer; Langerhans Cell Histiocytosis; Laryngeal Cancer; Leukemia, Acute Lymphoblastic; Leukemia, Acute Myeloid; Leukemia, Chronic Lymphocytic; Leukemia, Chronic Myelogenous; Leukemia, Hairy Cell; Lip and Oral Cavity Cancer; Liver Cancer; Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoma, AIDS-Related; Lymphoma, Burkitt; Lymphoma, Cutaneous T-Cell; Lymphoma, Hodgkin; Lymphoma, Non-Hodgkin; Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom; Malignant Fibrous Histiocytoma of Bone and Osteosarcoma; Medulloblastoma; Melanoma; Melanoma, Intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma; Metastatic Squamous Neck Cancer with Occult Primary; Mouth Cancer; Multiple Endocrine Neoplasia Syndrome, (Childhood); Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Neuroblastoma; Non-Small Cell Lung Cancer; Oral Cancer; Oral Cavity Cancer; Oropharyngeal Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Islet Cell Tumors; Papillomatosis; Parathyroid Cancer; Penile Cancer; Pharyngeal Cancer; Pheochromocytoma; Pineal Parenchymal Tumors of Intermediate Differentiation; Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors; Pituitary Tumor; Plasma Cell Neoplasm/Multiple Myeloma; Pleuropulmonary Blastoma; Primary Central Nervous System Lymphoma; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Pelvis and Ureter, Transitional Cell Cancer; Respiratory Tract Carcinoma Involving the NUT Gene on Chromosome 15; Retinoblastoma; Rhabdomyosarcoma; Salivary Gland Cancer; Sarcoma, Ewing Family of Tumors; Sarcoma, Kaposi; Sarcoma, Soft Tissue; Sarcoma, Uterine; S6zary Syndrome; Skin Cancer (Nonmelanoma); Skin Cancer (Melanoma); Skin Carcinoma, Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma, Squamous Neck Cancer with Occult Primary, Metastatic; Stomach (Gastric) Cancer; Supratentorial Primitive Neuroectodermal Tumors; T-Cell Lymphoma, Cutaneous; Testicular Cancer; Throat Cancer; Thymoma and Thymic Carcinoma; Thyroid Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Urethral Cancer; Uterine Cancer, Endometrial; Uterine Sarcoma; Vaginal Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; or Wilms Tumor. 52. The method according to claim 1, wherein the cancer is chosen from renal cell carcinoma, lung cancer, malignant melanoma, or pancreatic cancer.

Details for Patent 8,883,832

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2029-07-06
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2029-07-06
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2029-07-06
Hemispherx Biopharma, Inc.	ALFERON N INJECTION	interferon alfa-n3 (human leukocyte derived)	Injection	103158	10/10/1989		2029-07-06